Patents, Licensing and other Legal Implications of Stem Cell Research to be Discussed at Industry Meeting October 8th, 9th in San Diego


Story Filed: Wednesday, August 21, 2002 8:01 AM EST

NEW YORK, Aug 21, 2002
Legal issues relating to stem cell research and regenerative medicine will be addressed during an audience interactive panel entitled "Stem Cells: Patents, Licensing and Intellectual Property", and will be moderated by Wisconsin Alumni Research Foundation/WiCell.

The panel is part of the 2nd Stem Cells and Regenerative Medicine: Commercial Implications for the Pharmaceutical and Biotech Industries meeting, to take place October 8th and 9th, in San Diego California.

The first meeting was held in Princeton NJ, and drew approximately 150 scientists, clinicians and executives from the pharmaceutical and biotech industries, as well as from academia.

Scientific topics covered will include embryonic, bone, pancreatic and umbilical stem cells, cell therapy, tissue regeneration/spinal cord repair and therapeutic cloning (nuclear transfer technology). Presentations will be given by Aastrom Bioscience, Advanced Cell Technology, Inc., Bresagen, Curis, Layton Bioscience, PPL Therpeutics, Harvard Medical School, Stanford University Medical School, among others.

To register, request announcement and list of past registrants, and/or for sponsorship/exhibition information, please contact Steve J. Kuperberg at skuperberg@srinstitute.com (please include company/university mailing address).

"If the wind could blow my troubles away. I'd stand in front of a hurricane."